Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.
Keywords: Bebtelovimab; COVID-19; Molnupiravir; Nirmatrelvir; Remdesivir; SARS-CoV-2; Tixagevimab/cilgavimab.
Copyright © 2022 Elsevier Inc. All rights reserved.